useful for the treatment of arrhythmogenic Channelopathies MicroRNA.

摘要

The present invention proposes the use of hsa-mir-219-5? microRNA, of SEQ ID NO: 1, of the modified polynucleotides derived therefrom, SEQ ID NO: 3 or SEQ ID NO: 5, or of the precursors thereof, SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6, for producing drugs that can be used to treat arrhythmogenic channelopathies, preferably those caused by changes in cardiac sodium channel function, more preferably long QT syndrome type 3 and Brugada syndrome. These polynucleotides are capable of modulating cardiac sodium channel function by means of the binding thereof to the mRNA of the SCN5A gene.